ewsba.se
Natera, Inc. (NASDAQ:NTRA) is one of the Stocks that Billionaire Druckenmiller and Jim Cramer like.
William Blair initiated coverage of Natera, Inc. (NASDAQ:NTRA) with an Outperform rating on the company’s stock on April 14, 2026. The firm recommends the stock as a core, long-term growth holding. William Blair highlights Natera, Inc. (NASDAQ:NTRA)’s leadership in major diagnostic markets and its diversified, expanding portfolio, positioning the company as a top investment choice in the medical technology sector.
Separately, on April 13, 2026, Natera, Inc. (NASDAQ:NTRA) highlighted positive interim results from Allogene Therapeutics’ (ALLO) registrational ALPHA3 trial, which uses the company’s CLARITY MRD assay. The study evaluates cema-cel CAR T therapy in patients with large B-cell lymphoma who remain positive for molecular residual disease (MRD) after initial treatment. Analysis showed 58.3% of MRD-positive patients achieved clearance with cema-cel. Median plasma ctDNA levels went down 97.7% in the treatment arm, compared to a 26.6% increase in the observation group. These findings offer early evidence of drug performance and reflect Natera, Inc. (NASDAQ:NTRA)’s phased variant technology in identifying high-risk patients.
Notably, the fourth quarter of 2025 established the stock as the largest holding at 12.8% of Druckenmiller’s portfolio. While acknowledging its growth in diagnostic testing, Jim Cramer takes a cautious view of the company.
Founded in 2003, Natera, Inc. (NASDAQ:NTRA) is a leader in cell-free DNA (cfDNA) and genetic testing. The Texas-based company specializes in high-sensitivity molecular diagnostics across three primary domains: women’s health (NIPT), oncology (MRD), and organ health (transplant rejection).
While we acknowledge the potential of NTRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 New Contenders for S&P 500 Index and Harvard University Stock Portfolio: Top 10 Stock Picks.
Disclosure: None. Follow Insider Monkey on Google News.